ARCHIVES

Rosenberg Starts New Study With TIL; LAK-IL-2 Costs Clarified

This article is from The Cancer Letter archive.

Vol. 12 No. 46 | November 28, 1986

Download PDF Visit The Full Archive

Related Articles

Accelerated Approval Will No Longer Block Competitors, FDA Commissioner Says

June 6, 2003

Arimidex Gets Full Approval For HR+ Early Breast Cancer

September 30, 2005

Sharfstein To Leave FDA

January 7, 2011

Merger Of Centers, Control Programs An Option, Upton Says; ACS To Fund New Prevention Centers

February 2, 1979

National Coalition Dinner Honors Cancer Program Founders, Advocates, And Cancer Survivors

March 6, 1992

Analysis Finds Exercise Lowers Colon Cancer Risk

February 27, 2009